BX-471

BX-471 (also known as ZK-811752 or BAY 86-5047) is a potent, selective, non-peptide small molecule antagonist of the CC chemokine receptor type 1 (CCR1). Originally developed by Berlex and its parent company Schering AG (later acquired by Bayer), the compound was designed to inhibit the recruitment of inflammatory cells, such as monocytes and T-cells, to sites of inflammation by blocking the binding of ligands like CCL3 (MIP-1α) and CCL5 (RANTES). BX-471 was evaluated in Phase 2 clinical trials for several inflammatory and autoimmune conditions, including endometriosis-associated pelvic pain, multiple sclerosis, psoriasis, and Alzheimer's disease. In the context of endometriosis, it was studied for its potential to reduce pain by modulating the inflammatory environment within the peritoneal cavity. However, development for these indications appears to have been discontinued as no recent clinical activity has been reported.

Other names

CCR1 antagonist BayerCCR-1 antagonist BayerCCR 1 antagonist Bayer